2 unknown, 1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow Immunosuppressive Treatment: new trials by email Literature Review of Immunosuppressive Treatment trials Research Report on Immunosuppressive Treatment
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia Dose-attenuated IST and Hetrombopag - Sever Aplastic Anaemia, Elderly (People Aged 65 or More) | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 65 | 2025-02-01 | 2025-06-08 |
| Multicenter Registry of Pediatric Lupus Nephritis in China Corticosteroid, Hydroxychloroquine, Cyclophosphamide - Lupus Nephritis, Children | Unknown | Xiqiang Dang | 1200 | 2018-12-01 | 2019-04-05 | |
| Registry of IgA Nephropathy in Chinese Children Corticosteroid, Cyclophosphamide, Mycophenolate mofetil - IgA Nephropathy, Proteinuria in Nephrotic Range | Unknown | Peking University First Hospital | 1200 | 2016-01-01 | 2023-12-06 |
Glomerulonephritis, IGA (1) · Lupus Nephritis (1)
Autoimmune Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Glomerulonephritis (2) · Immune System Diseases (2) · Kidney Diseases (2) · Male Urogenital Diseases (2) · Nephritis (2) · Urogenital Diseases (2) · Urologic Diseases (2) · Connective Tissue Diseases (1) · Lupus Erythematosus, Systemic (1) · Skin and Connective Tissue Diseases (1)
Adrenal Cortex Hormones (2) · Cyclophosphamide (2) · Mycophenolic Acid (2) · Prednisolone (2) · Prednisone (2) · Steroids (2) · Angiotensin Receptor Antagonists (1) · Angiotensin-Converting Enzyme Inhibitors (1) · Azathioprine (1) · Cyclosporine (1) · Dipyridamole (1) · Hydroxychloroquine (1) · Rituximab (1) · Tacrolimus (1) · deflazacort (1)
Institute of Hematology & Blood Diseases Hospital, China (1) · Peking University First Hospital (1) · Xiqiang Dang (1)
China (3)
Jie Ding, Prof. (1) · Jun Shi, PhD (1)